四氟醚唑 | 112281-77-3

• 物质功能分类: 分析化学 - 标准品 - 化妆品标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 四氟醚唑
• 中文别名: 氟醚唑；2-(2,4-二氯苯基)-3-(1H-1,2,4-三唑-1-基)丙基1,1,2,2,-四氟乙基醚；(±)-2-(2,4-二氯苯基)-3-(1H-1,2,4-三唑-1-基)丙基-1,1,2,2-四氟乙基醚；(±)-2-(2，4-二氟苯基)-3-(1H-1，2，4-三唑-1-基)丙基1，1，2，2-四氟乙基醚；四氟醚唑；2-(2,4-二氯苯基)-3-(1H-1,2,4-三唑-1-基)丙基 1,1,2,2,-四氟乙基醚
• 英文名称: (RS)-2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl 1,1,2,2-tetrafluoroethyl ether
• 英文别名: (+/-)-1-[2-(2,4-dichlorophenyl)-3-(1,1,2,2-tetrafluoroethoxy)propyl]-1H-1,2,4-triazole；2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl 1,1,2,2,-tetrafluoroethyl ether；2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl 1,1,2,2-tetrafluoroethyl ether；2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethyl ether；2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether；1-[2-(2,4-dichlorophenyl)-3-(1,1,2,2-tetrafluoroethoxy)propyl]-1H-1,2,4-triazole；Tetraconazole；1-[2-(2,4-dichlorophenyl)-3-(1,1,2,2-tetrafluoroethoxy)propyl]-1,2,4-triazole
• CAS: 112281-77-3
• 化学式: C₁₃H₁₁Cl₂F₄N₃O
• mdl: MFCD01632314
• 分子量: 372.149
• InChiKey: LQDARGUHUSPFNL-UHFFFAOYSA-N

物化性质

• 熔点：
  6 °C
• 沸点：
  438.4±55.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)
• LogP：
  3.560
• 颜色/状态：
  Colorless, viscous liquid
• 溶解度：
  In water, 150 mg/L at 20 °C
• 蒸汽压力：
  1.35X10-6 mm Hg at 20 °C
• 分解：
  Decomposition at 240 °C (boiling point) /from table/
• 碰撞截面：
  174.34 Ų [M+H]+ [CCS Type: TW]
• 保留指数：
  2013;1998;1985.6

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.384
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  7

ADMET

代谢

三只 Sprague-Dawley 大鼠/性别通过口服灌胃给予1.25 mg/kg的(14C-U-三唑基)四康唑(放射性纯度：96.34%，比活性：41.72 uCi/mg)。未标记的四康唑用于将给药准备液的比活性调整为50 uCi/kg。在给药后特定时间间隔内收集尿液和粪便，直至72小时。尿液是主要的排泄途径，雄性和雌性大鼠分别有71%和62%的给药剂量在那里恢复。另外，雄性和雌性大鼠的粪便中分别恢复了19%和26%。尿液中恢复的主要代谢物是三唑(雄性和雌性分别为64%和41%)。尿样中的β-葡萄糖醛酸酶介导的水解并没有在很大程度上改变代谢轮廓。未代谢的四康唑是雌性大鼠粪便中恢复的主要放射性标记物，占给药剂量的8.8%。M14360-DCP-3OH是雄性大鼠粪便中的主要代谢物，占给药剂量的3.5%，其次是三唑(1.9%)和M14360-DCP-5OH (1.2%)。在实验附录中，M14360-DFA在雌性大鼠尿液中被发现。这种恢复占给药剂量的1.2%。

Three Sprague-Dawley rats/sex were dosed orally by gavage with 1.25 mg/kg of (14C-U-triazolyl) tetraconazole (radiochemical purity: 96.34%, specific activity: 41.72 uCi/mg). Unlabeled tetraconazole was used to adjust the specific acitivity of the dosing preparation to 50 uCi/kg. Urine and feces were collected at specific time intervals up to 72 hours post-dose. Urine was the primary route of excretion with 71 and 62% of the administered dose recovered there for the males and females, respectively. An additional 19 and 26% was recovered in the feces of the males and females respectively. The primary metabolite recovered in the urine was triazole (64 and 41% for the males and females, respectively). Beta-glucuronidase-mediated hydrolysis of the urine samples did not greatly alter the metabolic profile. Unmetabolized tetraconazole was the primary radiolabeled moiety recovered in the feces of the females, 8.8% of the administered dose. M14360-DCP-3OH was the primary metabolite in the feces of the males, 3.5% of the administered dose, followed by triazole (1.9%) and M14360-DCP-5OH (1.2%). In the Experimental Addendum..., M14360-DFA was identified in the urine of the female rats. This recovery constituted 1.2% of the administered dose.

来源:Hazardous Substances Data Bank (HSDB)

代谢

来自两种治疗方案的单一剂量和多剂量治疗的前48小时口服给药的Crl:CD BR大鼠（雌雄各半）的汇集尿液和粪便样本，剂量为5或60 mg/kg的(14C)-Phenyl M 14360（放射性纯度：97.99%，比活性：37.33 mCi/mmole）...通过GC/MS分析了放射性标记的代谢物。母体的氧化和还原导致在尿液和粪便中分别回收了M 14360酸和M14360醇，两种性别和两种治疗水平下的两种治疗方案均有此现象。母体中的三唑环被谷胱甘肽取代并随后代谢，导致回收了亚砜（P1）和N-乙酰半胱氨酸（P4）结合物。P1、P4和M 14360酸在尿液中回收。P4、M 14360和M 14360醇在粪便中回收。额外的代谢物P2和P3在尿液中回收，P5在粪便中分离。这些部分的结构的尚未阐明。未识别的放射性标记部分在两种治疗水平和两种治疗方案下构成了15至33%的给药剂量。

Pooled urine and fecal samples derived from the first 48 hours post-dose of both single dose and multiple dose treatment regimens in which Crl:CD BR rats of both sexes were dosed orally by gavage with 5 or 60 mg/kg of (14C)-Phenyl M 14360 (radiochemical purity: 97.99%, specific activity: 37.33 mCi/mmole)... were analyzed for radiolabeled metabolites by means of GC/MS. Oxidation and reduction of the parent compound resulted in the recovery of the M 14360 acid in the urine and the M14360 alcohol in the feces of both sexes at both treatment levels for both treatment regimens. Displacement of the triazole ring from the parent compound by glutathione and subsequent metabolism resulted in the recovery of the sulfoxide (P1) and the N-acetylcysteine (P4) conjugates. P1, P4 and M 14360 acid were recovered in the urine. P4, M 14360 and M 14360 alcohol were recovered in the feces. Additional metabolites, P2 and P3, were recovered in the urine and P5 was isolated in the feces. The structures of these moieties were not elucidated. The unidentified radiolabeled moieties constituted 15 to 33% of the administered dose for both treatment levels under both treatment regimens.

来源:Hazardous Substances Data Bank (HSDB)

代谢

... 三唑是尿液和粪便中的主要代谢物。在尿液中，除了M-14360酸外，还分离出了少量的M-14360醇及其葡萄糖醛酸苷结合物（M3）。在粪便中，分离出了少量的原药M-14360、酸和醇。 ...

... Triazole was the major metabolite identified in the urine and feces. In the urine M-14360 acid along with minor metabolite of M-14360 alcohol and its glucuronide conjugate (M3) were isolated. In the feces minor amounts of parent M-14360, the acid and alcohol were isolated. ...

来源:Hazardous Substances Data Bank (HSDB)

代谢

Tetraconazole results in the formation of 1,2,4-三唑（T）、三唑基丙氨酸（TA）、三唑基乙酸（TAA）以及三唑基羟基丙酸（THP）。

Tetraconazole results in the formation of /1,2,4-triazole (T), triazolyl alanine (TA), triazolyl acetic acid (TAA)/ as well as /triazolyl hydroxypropionic acid/ (THP).

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌性证据

癌症分类：可能对人类致癌

Cancer Classification: Likely to be Carcinogenic to Humans

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌性证据

四唑醇被归类为可能对人类有致癌性的物质，这一判断基于雄性和雌性小鼠肝脏肿瘤的发生。致癌性评估审查委员会建议对实验动物肿瘤数据应用低剂量外推模型，并估计四唑醇对雄性和雌性小鼠肝脏肿瘤的风险量化。机构在进行终身癌症风险评估时，将使用最有效的单位风险。在这种情况下，最有效的单位风险Q1*是指雄性小鼠肝脏良性及/或恶性肿瘤率在人类等效剂量为2.30 x 10^-2。

Tetraconazole was classified as likely to be carcinogenic to humans based on the occurrence of liver tumors in male and female mice. The Carcinogenicity Assessment Review Committee recommended that a low dose extrapolation model be applied to the experimental animal tumor data and that quantification of risk be estimated for male and female mouse liver tumors for Tetraconazole. The most potent unit risk will be used for the purpose of lifetime cancer risk assessment by the Agency. In this case, the most potent unit risk, Q1*, is that for male mouse liver benign and/or malignant combined tumor rates at 2.30 x 10-2 in human equivalents.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 致癌物分类

对人类不具有致癌性（未被国际癌症研究机构IARC列名）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 人类毒性摘录

如果吞咽或通过皮肤吸收，有害。会引起中度眼睛刺激。/四唑醇技术/

/SIGNS AND SYMPTOMS/ Harmful if swallowed or absorbed through skin. Causes moderate eye irritation. /Tetraconazole technical/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

/遗传毒性/ Hela S3细胞在非活化条件和活化条件下，于37°C下暴露于M 14360技术级（纯度：94.6%）的浓度范围为0.25至512微克/毫升，持续3小时。每个处理水平都进行了两次试验，使用复制的平板。使用了来自预先用Aroclor 1254处理的鼠肝的S9组分来代谢试验材料。在非活化或活化条件下，没有观察到与处理相关的净颗粒计数明显增加。

/GENOTOXICITY/ Hela S3 cells were exposed to M 14360 technical (purity: 94.6%) at concentrations ranging of 0.25 to 512 ug/mL for 3 hours at 37 °C under conditions of non-activation and activation. Two trials were performed with duplicate plates for each treatment level. An S9 fraction derived from the liver of rats pretreated with Aroclor 1254 was used to metabolize the test material. There was no apparent treatment-related increase in the net grain count under conditions of either nonactivation or activation.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

两只Crl:CD大鼠/性别/每组通过口服灌胃给予5或60毫克/千克的Triazole-14C-ASC-66811（M14360）（放射性纯度：>99%，比活性：42 mCi/mmole）。未标记的ASC-66811（纯度：99.7%）用于调整给药准备液的比活性。在指定的时间间隔内收集尿液、二氧化碳和粪便样本，直至给药后168小时。在给药后168小时检查组织中放射性标记的分布。通过尿液排泄是主要的途径，79到95%的给予的放射性标记在尿液中回收。12到16%的放射性标记在粪便中回收。在较低剂量水平下，雄性和雌性分别在给药后前24小时内排泄了61和27%的给药剂量。在较高剂量下，雄性和雌性在给药后前24小时内分别排泄了28和8%的剂量。在呼出的空气中回收的放射性标记占给药剂量的0.13到0.23%。组织中的残留放射性标记占给药剂量的0.7到1.9%。在给药后7天内，放射性标记没有在特定组织中富集。

Two Crl:CD rats/sex/group were dosed orally by gavage with 5 or 60 mg/kg of Triazole-14C-ASC-66811 (M14360) (radiochemical purity: >99%, specific activity: 42 mCi/mmole). Unlabelled ASC-66811 (purity: 99.7%) was used to adjust the specific activity of the dosing preparations. Urine, carbon dioxide, and fecal samples were collected at designated intervals up to 168 hours post-dose. The distribution of radiolabel in the tissues was examined at 168 hours post-dose. Excretion via the urine was the primary pathway with 79 to 95% of the administered radiolabel recovered in the urine. Twelve to 16% of the radiolabel was recovered in the feces. At the lower dosing level, 61 and 27% of the administered dose was excreted within the 1st 24 hours post-dose for the males and females, respectively. At the higher dose, 28 and 8% of the dose was excreted during the 1st 24 hours for the males and female, respectively. Recovery of the radiolabel in the exhaled air ranged from 0.13 to 0.23% of the administered dose for both dose levels. The residual radiolabel in the tissues ranged from 0.7 to 1.9% of the administered dose. The radiolabel was not sequestered in a particular tissue at 7 days post-dose.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

两只Crl:CD大鼠/性别/每组通过口服灌胃给予5或60毫克/千克的[U-14C-phenyl]-ASC-66811（M14360）（放射性纯度：99.3%（TLC），99.0%（HPLC））。未标记的ASC-66811（纯度：94.0%）用于调整给药准备物的特定活性。在指定的时间间隔内收集尿液、二氧化碳和粪便样本，直至给药后168小时。在给药后168小时检查组织中放射性标记的分布。通过尿液排泄是主要的途径，70至79%的给药放射性标记在尿液中回收。21至32%的放射性标记在粪便中回收。在较低剂量水平下，雄性和雌性分别在给药后前24小时内排泄了70和57%的给药剂量。在较高剂量下，雄性和雌性分别在给药后前24小时内排泄了64和21%的剂量。呼出气体中放射性标记的回收量最小。组织中残留的放射性标记占剂量的不到1%。在给药后7天，肾脏是主要的回收部位。

Two Crl:CD rats/sex/group were dosed orally by gavage with 5 or 60 mg/kg of [U-14C-phenyl]-ASC-66811 (M14360) (radiochemical purity: 99.3% (TLC), 99.0% (HPLC)). Unlabelled ASC-66811 (purity: 94.0%) was used to adjust the specific activity of the dosing preparations. Urine, carbon dioxide, and fecal samples were collected at designated intervals up to 168 hours post-dose. The distribution of radiolabel in the tissues was examined at 168 hours post-dose. Excretion via the urine was the primary pathway with 70 to 79% of the administered radiolabel recovered in the urine. Twenty one to 32% of the radiolabel was recovered in the feces. At the lower dosing level, 70 and 57% of the administered dose was excreted within the 1st 24 hours post-dose for the males and females, respectively. At the higher dose, 64 and 21% of the dose was excreted during the 1st 24 hours for the males and female, respectively. Recovery of the radiolabel in the exhaled air was minimal. The residual radiolabel in the tissues constituted <1% of the dose. The kidneys were the primary site of recovery at 7 days post-dose.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

每性别每组三只Crl:CD BR大鼠口服灌胃给予5或60 mg/kg的(14C)-苯基M 14360（放射性纯度：96.90%，比活度：37.35 mCi/mmol）。未标记的M 14360技术级（纯度：97.6%）用于调整给药制剂的比活度。每性别有一只动物仅给予载体。在给药后指定时间从每只研究动物抽取血液。通过燃烧每个样本并回收放射性标记的二氧化碳，然后通过液体闪烁计数分析，确定每个样本中回收的放射性标记。由于每个处理组中最高放射性水平都是在第一个采样时间记录的，因此无法确定放射性标记的最大血药浓度。报告的所有处理组血液中放射性标记的半衰期相似，所有组的平均值为16.3小时。同样，消除速率也相似，平均值为0.044 ng当量/克/小时。

Three Crl:CD BR rats/sex/group were dosed orally by gavage with 5 or 60 mg/kg of (14C)-Phenyl M 14360 (radiochemical purity: 96.90%, specific activity: 37.35 mCi/mmole). Unlabeled M 14360 technical (purity: 97.6%) was used to adjust the specific activity of the dosing preparations. One animal/sex was dosed with the vehicle alone. Blood was drawn at specified times post-dose from each of the study animals. The radiolabel recovered from each sample was determined by combustion of the sample and recovery of the radiolabeled carbon dioxide which was then analyzed by liquid scintillation counting. The maximal blood concentration of the radiolabel could not be determined because the highest level of radioactivity was recorded for the first sample time in each of the treatment groups. The reported half-lives for the radiolabel in the blood were comparable for all of the treatment groups with a mean for all of the groups of 16.3 hours. Likewise the rates of elimination were comparable with the mean value being 0.044 ng equivalents/g/hour.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

每组5只雄性和5只雌性CD BR大鼠，通过口服灌胃的方式给予5或60毫克/千克的（14C）-苯基M 14360（放射性纯度：97.99%，比活性：37.33 mCi/mmole）。未标记的M 14360（纯度：97.6%）用于调整给药准备液的比活性。每组有两只动物仅给予载体。在治疗后指定的时间间隔内，从每个组的动物中收集尿液、粪便和笼子洗涤样本。动物在给药后72小时被安乐死。放射性标记物的血药浓度峰值时间从5毫克/千克雄性动物的1.2小时后到60毫克/千克雌性动物的19.2小时后不等。所有治疗组的血液半衰期大约为15小时。尿液是主要的排泄途径，72小时后，62至70%的给药剂量通过尿液和笼子洗涤液回收，对于两个治疗水平都是如此。这些组的粪便回收率在25至36%之间。在给药后72小时，2.8至5.8%的给药剂量在组织中回收。胃肠道和肝脏是主要的回收部位。

Five Crl:CD BR rats/sex/group were dosed orally by gavage with 5 or 60 mg/kg of (14C)-Phenyl M 14360 (radiochemical purity: 97.99%, specific activity: 37.33 mCi/mmole). Unlabeled M 14360 (purity: 97.6%) was used to adjust the specific activity of the dosing preparations. Two animals/sex were dosed only with the vehicle. Urine, feces and cage wash samples were collected from each of the groups at designated time intervals after treatment. The animals were euthanized at 72 hours post-dose. The time-to-peak blood levels for the radiolabel ranged from 1.2 hours post-dose for the 5 mg/kg males to 19.2 hours post-dose for the 60 mg/kg females. The half-life in the blood was approximately 15 hours for all of the treatment groups. The urine was the primary pathway of excretion with 62 to 70% of the administered dose being recovered in the urine and cage wash by 72 hours post-dose for both treatment levels. The recovery in the feces from these groups ranged from 25 to 36%. At 72 hours post-dose, 2.8 to 5.8% of the administered dose was recovered in the tissues. The gastrointestinal tract and the liver were the primary sites of recovery.

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 危险品标志：
  Xn,N
• 安全说明：
  S36/37,S41,S61
• 危险类别码：
  R20/22,R51/53,R40
• WGK Germany：
  3
• 危险品运输编号：
  UN 3082 9 / PGIII
• 储存条件：
  0至6°C

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Tetraconazole
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 112281-77-3
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
Acute toxicity, Inhalation (Category 4), H332
Chronic aquatic toxicity (Category 2), H411
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R20/22
N Dangerous for the R51/53
environment
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 + H332 Harmful if swallowed or if inhaled
H411 Toxic to aquatic life with long lasting effects.
Precautionary statement(s)
P273 Avoid release to the environment.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C13H11Cl2F4N3O
Molecular Weight : 372,15 g/mol
CAS-No. : 112281-77-3
EC-No. : 407-760-6
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
(+/-) 2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether
Acute Tox. 4; Aquatic Chronic -
2; H302 + H332, H411
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas, Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: viscous
Colour: yellow
b) Odour aromatic
c) Odour Threshold no data available
d) pH 5,47
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure 0,0000018 hPa
l) Vapour density no data available
m) Relative density 1,4382 g/cm3 at 20 °C
n) Water solubility 0,159 g/l at 20 °C
o) Partition coefficient: n- log Pow: 3,56 at 23 °C
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
Solubility in other Acetone
solvents

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Acids, Water, Reducing agents, Carbon oxides, Oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
LD50 Oral - rat - male - 1.248 mg/kg
Inhalation: no data available
Dermal: no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
Toxicity to fish LC50 - Lepomis macrochirus (Bluegill sunfish) - 5,8 mg/l - 96 h
- Oncorhynchus mykiss (rainbow trout) - 5,1 mg/l - 96 h
Toxicity to daphnia and EC50 - Daphnia magna (Water flea) - 2,63 mg/l - 48 h
other aquatic
invertebrates
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
Toxic to aquatic life with long lasting effects.

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 3082 IMDG: 3082 IATA: 3082
UN proper shipping name
ADR/RID: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. ((+/-) 2-(2,4-
dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether)
IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. ((+/-) 2-(2,4-
dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether)
IATA: Environmentally hazardous substance, liquid, n.o.s. ((+/-) 2-(2,4-dichlorophenyl)-3-(1H-1,2,4-
triazol-1-yl)propyl-1,1,2,2-tetrafluoroethylether)
Transport hazard class(es)
ADR/RID: 9 IMDG: 9 IATA: 9
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: yes IMDG Marine pollutant: yes IATA: yes
Special precautions for user
Further information
EHS-Mark required (ADR 2.2.9.1.10, IMDG code 2.10.3) for single packagings and combination
packagings containing inner packagings with Dangerous Goods > 5L for liquids or > 5kg for solids.

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

理化性质

原药为黄色或棕黄色液体，纯品则呈现无色且黏稠的油状物，熔点在6℃，沸点约240℃（分解但未沸腾）。相对密度1.432（21℃），蒸气压为0.018mPa（20℃），分配系数Kow lgP=3.56（20℃），Henry常数为3.6×10^-4Pa·m^3/mol（计算）。在20℃、pH 7的水中的溶解度约为183.8mg/L。该物质能快速溶解于丙酮、二氯甲烷和甲醇中。稳定性方面，其水溶液对日光稳定，在pH4~9时不会发生水解。

应用

氟醚唑适用于禾谷类作物（如小麦、大麦、燕麦、黑麦等）、果树（如香蕉、葡萄、梨、苹果等）、蔬菜、甜菜及观赏植物等多种作物的病害防治。能够有效预防白粉菌属、柄锈菌属、喙孢属、核腔菌属和壳针孢属菌引起的多种疾病，包括小麦白粉病、小麦散黑穗病、小麦锈病、小麦腥黑穗病、小麦颖枯病、大麦云纹病、大麦散黑穗病、大麦纹枯病、玉米丝黑穗病、高粱丝黑穗病、瓜果白粉病、香蕉叶斑病、苹果斑点落叶病和梨黑星病以及葡萄白粉病等。

氟醚唑的使用方法包括茎叶处理或种子处理。对于茎叶喷雾，防治禾谷类作物和甜菜病害时建议用量为100～125g（a.i.）/hm^2；用于葡萄、观赏植物、仁果、核果等作物时建议用量为20～50g(a.i.)/hm^2；对于蔬菜病害防治推荐剂量为40～60g(a.i.)/hm^3；对于甜菜则建议使用量为60～100g（a.i.）/hm^2。此外，种子处理时的推荐剂量通常在每百公斤种子中加入10～30g。

毒性

氟醚唑对雄大鼠和雌大鼠急性经口LD50分别为1248mg/kg和1031mg/kg；皮肤接触毒性方面，大鼠急性经皮LD50大于2000mg/kg。兔眼睛轻微刺激，但对兔皮肤无刺激性。吸入毒性中大鼠LC50（4小时）超过3.66mg/L。NOEL数据显示，大鼠长期暴露的LOAEL为3.9mg/(kg·d)，而其NOAEL则为0.5mg/(kg·d)；同理，公狗2.95mg/(kg·d)和母狗3.33mg/(kg·d)也未见有害效应。根据EC计算得出的ADI值为0.004mg/kg（2008年），EPA最低aRfD为0.225，cRD为0.0073mg/kg（2005年）。氟醚唑无致癌、致突变和生殖毒性。

作用机制

氟醚唑是一种甾醇脱甲基化抑制剂。由于其优异的内吸性特性，可迅速被植物吸收并在内部传导，从而表现出出色的保护和治疗活性。其持效期长达6周。

环境行为

动物口服后，氟醚唑易在体内被快速吸收，未见显著代谢或排泄过程。大鼠尿液中的主要代谢产物为1,2,4-三唑。在植物体内则有多个代谢物，包括四氟醚唑酸、四氟醚唑醇、三唑胺和三唑乙酸等。土壤中没有积累现象，在不同类型的土壤中Koc值范围从531到1922不等。

反应信息

• 作为反应物：
  描述：

  四氟醚唑 在 Chiralcel OD-RH (cellulose tris-(3,5-dimethylphenylcarbamate)) chiral column 作用下， 以 乙醇 、 正己烷 为溶剂， 生成 (-)-S-tetraconazole 、 (+)-R-1-[2-(2,4-dichlorophenyl)-3-(1,1,2,2-tetrafluoroethoxy)propyl]-1H-1,2,4-triazole
  参考文献：
  名称：

  手性高效液相色谱对映体选择性测定三唑真菌四康唑及其在黄瓜，香瓜和土壤中的药代动力学研究

  摘要：

  开发了一种简单的具有二极管阵列检测器的手性高效液相色谱方法，并已验证可用于立体选择性测定黄瓜，香瓜和土壤中的四康唑对映体。良好的分离在20实现℃下使用纤维素三（4-甲基苯甲酸酯）作为手性固定相的混合物，Ñ以0.8毫升/分钟的流速-己烷和乙醇（90:10）作为流动相。该测定方法在一定浓度范围（0.5–50μg/ ml）内呈线性，两种对映体的平均回收率均在85％以上。植物和土壤样品中两种对映体的检出限分别为0.06和0.12μg/ g。将该方法成功地应用于rac的对映选择性降解研究。黄瓜，甜瓜和土壤中的四康唑。结果表明，在黄瓜，甜瓜和北京土壤中，四康唑的两种对映体的降解遵循一级动力学，并且具有明显的立体选择性。（-）- S-四康唑的优先吸收和降解导致植物样品中的（+）- R-四康唑残基富集，而（+）- R-四康唑在北京土壤中显示出更快的降解和立体选择性可能是由微生物引起的。在黑龙江土壤中未观察

  DOI：

  10.1002/chir.21997
• 作为产物：
  描述：

  2-(2,4-dichlorophenyl)-3-(1H-1,2,4-triazol-1-yl)propan-1-ol 生成 四氟醚唑
  参考文献：
  名称：

  Fungicidal azolyl-derivatives

  摘要：

  本发明涉及具有以下式的化合物：##STR1## 其中：m = 0，1; n = 0，1; Z = CH，N; R.sub.1选自氯，溴，氟，CF.sub.3，苯基，C.sub.1-C.sub.2-烷氧基，C.sub.1-C.sub.2-卤代烷氧基，烷硫基和卤代烷硫基，其中卤素为Cl，Br，F; R.sub.2为H，氟，氯或溴; R.sub.3表示H，CH.sub.3，CN，或者当m = 1或n = 1且R.sub.4，R.sub.5为H时也可以是F; R.sub.4，R.sub.5独立地为H或F; 当m = 0时，R.sub.3和R.sub.4还可以表示在式(I)中它们所连接的两个碳原子之间的第二个键; R.sub.f选自包含高达4个碳原子，至少含有2个F原子和可选的其他卤素（Cl和Br）的聚氟烷基，聚氟烯基和聚氟炔基的群。包含这些新化合物的抗真菌组合物。

  公开号：

  US05081141A1

文献信息

• [EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
  申请人：GILEAD APOLLO LLC

  公开号：WO2017075056A1

  公开（公告）日：2017-05-04

  The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.

  本发明提供了化合物I和II，这些化合物可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及它们的组合物和使用方法。
• [EN] BICYCLYL-SUBSTITUTED ISOTHIAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS ISOTHIAZOLINE SUBSTITUÉS PAR UN BICYCLYLE
  申请人：BASF SE

  公开号：WO2014206910A1

  公开（公告）日：2014-12-31

  The present invention relates to bicyclyl-substituted isothiazoline compounds of formula (I) wherein the variables are as defined in the claims and description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及公式（I）中变量如索权和说明中所定义的自行车基取代异噻唑啉化合物。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种通过使用这些化合物来控制无脊椎动物害虫的方法，以及包含所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] AZOLINE COMPOUNDS<br/>[FR] COMPOSÉS AZOLINE
  申请人：BASF SE

  公开号：WO2015128358A1

  公开（公告）日：2015-09-03

  The present invention relates to azoline compounds of formula (I) wherein A, B1, B2, B3, G1, G2, X1, R1, R3a, R3b, Rg1 and Rg2 are as defined in the claims and the description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.

  本发明涉及式（I）的噁唑啉化合物，其中A、B1、B2、B3、G1、G2、X1、R1、R3a、R3b、Rg1和Rg2如权利要求和描述中所定义。这些化合物对抗或控制无脊椎动物害虫，特别是节肢动物害虫和线虫方面具有用途。该发明还涉及一种利用这些化合物控制无脊椎动物害虫的方法，以及包括所述化合物的植物繁殖材料、农业和兽医组合物。
• [EN] SUBSTITUTED QUINAZOLINES AS FUNGICIDES<br/>[FR] QUINAZOLINES SUBSTITUÉES, UTILISÉES EN TANT QUE FONGICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2010136475A1

  公开（公告）日：2010-12-02

  The present invention relates to a compound of formula (I) wherein wherein the substituents have the definitions as defined in claim 1or a salt or a N-oxide thereof, their use and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.

  本发明涉及一种具有如下式（I）的化合物，其中取代基具有权利要求1中定义的定义，或其盐或N-氧化物，它们的用途以及用于控制和/或预防植物中微生物感染，特别是真菌感染的方法，以及制备这些化合物的方法。
• [EN] MICROBIOCIDAL OXADIAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXADIAZOLE MICROBIOCIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2017157962A1

  公开（公告）日：2017-09-21

  Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially fungicides.

  式(I)的化合物，其中取代基如权利要求1所定义，作为杀虫剂特别是杀菌剂有用。